Vamil Divan

Stock Analyst at Guggenheim

(2.54)
# 810
Out of 5,243 analysts
256
Total ratings
53.92%
Success rate
30.56%
Average return
43 Stocks
Name Action Price Target Current % Upside Ratings Updated
Keros Therapeutics
Downgrades: Neutral
n/a
n/a n/a 4 Dec 16, 2024
Pfizer
Maintains: Buy
35 33
26.25 25.71% 14 Dec 11, 2024
Revance Therapeutics
Maintains: Neutral
7 4
3.29 -5.78% 6 Dec 10, 2024
Absci
Reiterates: Buy
10 10
2.86 249.65% 2 Dec 3, 2024
Johnson & Johnson
Maintains: Neutral
156 162
144.71 11.95% 11 Nov 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
212 221
171.35 28.98% 19 Nov 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
56 64
33.91 88.73% 4 Oct 28, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
23 41
18.09 126.64% 7 Oct 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
6
1.57 282.17% 1 Sep 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
70 95
70.19 35.35% 4 Jul 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Jun 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
77 77
56.61 36.02% 8 Apr 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
55
n/a n/a 1 Apr 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
245 330
n/a n/a 7 Jan 26, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
19 20
7.26 175.48% 9 Sep 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
21 18
n/a n/a 2 Aug 18, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
26
0.4 6400% 2 Jun 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
35 40
n/a n/a 3 Jun 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
8 9
1.18 662.71% 2 Apr 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
n/a
n/a n/a 1 Mar 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
13 2
n/a n/a 5 Nov 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
27 19
17.47 8.76% 7 Aug 10, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
95 98
142.54 -31.25% 8 Aug 8, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
36 34
29.05 17.04% 7 Jul 28, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
20 10
2.21 352.49% 3 May 25, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
51 49
93.92 -47.83% 3 May 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
315 356
746.46 -52.31% 15 May 2, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
8 6
3.24 85.19% 1 Mar 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
144 154
35.98 328.02% 9 Mar 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
15
10.11 48.37% 5 May 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 6 Dec 13, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
7 4
n/a n/a 6 Nov 8, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
11 19
n/a n/a 8 Sep 17, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Neutral
35
n/a n/a 13 Aug 5, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Neutral
n/a
n/a n/a 13 Jul 10, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
36 30
n/a n/a 4 May 21, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
161 155
n/a n/a 10 Mar 7, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
71 81
100.2 -19.16% 7 Oct 11, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
15
4.93 204.26% 4 Aug 15, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
58 61
55.98 8.97% 5 Jul 27, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
103
2.21 4560.63% 3 Jan 17, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
45 55
n/a n/a 1 Sep 19, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
66 120
n/a n/a 4 Dec 20, 2016